questionsmedicales.fr
Actions chimiques et utilisations
Actions pharmacologiques
Mécanismes moléculaires de l'action pharmacologique
Inducteurs des enzymes du cytochrome P-450
Inducteurs du cytochrome P-450 CYP2D6
Inducteurs du cytochrome P-450 CYP2D6 : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Cytochrome P-450 CYP2D6
Inducteurs
Tests génétiques
Cytochrome P-450 CYP2D6
Efficacité des médicaments
Cytochrome P-450 CYP2D6
Cytochrome P-450 CYP2D6
Métabolisme des médicaments
Rifampicine
Carbamazépine
Symptômes
5
Symptômes
Cytochrome P-450 CYP2D6
Concentration plasmatique
Efficacité des médicaments
Effets secondaires
Cytochrome P-450 CYP2D6
Non-réponse au traitement
Cytochrome P-450 CYP2D6
Intoxication
Cytochrome P-450 CYP2D6
Prévention
5
Prévention
Interactions médicamenteuses
Éducation des patients
Cytochrome P-450 CYP2D6
Antécédents médicamenteux
Interactions médicamenteuses
Surveillance médicale
Cytochrome P-450 CYP2D6
Lignes directrices
Interactions médicamenteuses
Traitements
5
Ajustement de dose
Cytochrome P-450 CYP2D6
Inhibiteurs
Cytochrome P-450 CYP2D6
Antidépresseurs
Antipsychotiques
Médicaments non inducteurs
Cytochrome P-450 CYP2D6
Suivi médical
Efficacité des médicaments
Complications
5
Complications
Efficacité thérapeutique
Hospitalisations
Cytochrome P-450 CYP2D6
Risques
Interactions médicamenteuses
Gestion des complications
Cytochrome P-450 CYP2D6
Complications à long terme
Métabolisme
Facteurs de risque
5
Facteurs de risque
Variations génétiques
Âge
Cytochrome P-450 CYP2D6
Habitudes de vie
Cytochrome P-450 CYP2D6
Prédispositions génétiques
Cytochrome P-450 CYP2D6
Interactions médicamenteuses
Cytochrome P-450 CYP2D6
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Inducteurs du cytochrome P-450 CYP2D6 : Questions médicales les plus fréquentes",
"headline": "Inducteurs du cytochrome P-450 CYP2D6 : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Inducteurs du cytochrome P-450 CYP2D6 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-30",
"dateModified": "2025-02-24",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Inducteurs du cytochrome P-450 CYP2D6"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Inducteurs des enzymes du cytochrome P-450",
"url": "https://questionsmedicales.fr/mesh/D065693",
"about": {
"@type": "MedicalCondition",
"name": "Inducteurs des enzymes du cytochrome P-450",
"code": {
"@type": "MedicalCode",
"code": "D065693",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.349"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Inducteurs du cytochrome P-450 CYP2D6",
"alternateName": "Cytochrome P-450 CYP2D6 Inducers",
"code": {
"@type": "MedicalCode",
"code": "D065699",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Andrea Gaedigk",
"url": "https://questionsmedicales.fr/author/Andrea%20Gaedigk",
"affiliation": {
"@type": "Organization",
"name": "Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation, Department of Pediatrics, Children's Mercy Kansas City, Kansas City, Missouri, USA."
}
},
{
"@type": "Person",
"name": "J Steven Leeder",
"url": "https://questionsmedicales.fr/author/J%20Steven%20Leeder",
"affiliation": {
"@type": "Organization",
"name": "Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation, Department of Pediatrics, Children's Mercy Kansas City, Kansas City, Missouri, USA."
}
},
{
"@type": "Person",
"name": "Vincent S Staggs",
"url": "https://questionsmedicales.fr/author/Vincent%20S%20Staggs",
"affiliation": {
"@type": "Organization",
"name": "School of Medicine, University of Missouri-Kansas City, Kansas City, Missouri, USA."
}
},
{
"@type": "Person",
"name": "Robin E Pearce",
"url": "https://questionsmedicales.fr/author/Robin%20E%20Pearce",
"affiliation": {
"@type": "Organization",
"name": "Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation, Department of Pediatrics, Children's Mercy Kansas City, Kansas City, Missouri, USA."
}
},
{
"@type": "Person",
"name": "Yan Pan",
"url": "https://questionsmedicales.fr/author/Yan%20Pan",
"affiliation": {
"@type": "Organization",
"name": "Department of Biomedical Science, University of Nottingham, Malaysia Campus, Semenyih, Selangor, Malaysia."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Deaths from tuberculosis: differences between tuberculosis-related and non-tuberculosis-related deaths.",
"datePublished": "2023-09-01",
"url": "https://questionsmedicales.fr/article/37719730",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fpubh.2023.1207284"
}
},
{
"@type": "ScholarlyArticle",
"name": "Tuberculosis of the breast: a rare extra-pulmonary presentation of tuberculosis.",
"datePublished": "2024-07-29",
"url": "https://questionsmedicales.fr/article/39078781",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3855/jidc.19024"
}
},
{
"@type": "ScholarlyArticle",
"name": "Progress Toward Tuberculosis Elimination and Tuberculosis Program Performance - National Tuberculosis Indicators Project, 2016-2022.",
"datePublished": "2024-06-06",
"url": "https://questionsmedicales.fr/article/38833409",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.15585/mmwr.ss7304a1"
}
},
{
"@type": "ScholarlyArticle",
"name": "Childhood tuberculosis.",
"datePublished": "2022-08-10",
"url": "https://questionsmedicales.fr/article/35947056",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/QCO.0000000000000866"
}
},
{
"@type": "ScholarlyArticle",
"name": "Tuberculosis in pregnancy.",
"datePublished": "2022-07-31",
"url": "https://questionsmedicales.fr/article/36002371",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.bpobgyn.2022.07.006"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Actions chimiques et utilisations",
"item": "https://questionsmedicales.fr/mesh/D020164"
},
{
"@type": "ListItem",
"position": 3,
"name": "Actions pharmacologiques",
"item": "https://questionsmedicales.fr/mesh/D020228"
},
{
"@type": "ListItem",
"position": 4,
"name": "Mécanismes moléculaires de l'action pharmacologique",
"item": "https://questionsmedicales.fr/mesh/D045504"
},
{
"@type": "ListItem",
"position": 5,
"name": "Inducteurs des enzymes du cytochrome P-450",
"item": "https://questionsmedicales.fr/mesh/D065693"
},
{
"@type": "ListItem",
"position": 6,
"name": "Inducteurs du cytochrome P-450 CYP2D6",
"item": "https://questionsmedicales.fr/mesh/D065699"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Inducteurs du cytochrome P-450 CYP2D6 - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Inducteurs du cytochrome P-450 CYP2D6",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-14",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Inducteurs du cytochrome P-450 CYP2D6",
"description": "Comment identifier un inducteur du CYP2D6 ?\nQuels tests sont utilisés pour évaluer l'activité du CYP2D6 ?\nQuels signes indiquent une induction du CYP2D6 ?\nPeut-on mesurer l'activité du CYP2D6 ?\nQuels médicaments sont des inducteurs connus ?",
"url": "https://questionsmedicales.fr/mesh/D065699?mesh_terms=Tuberculosis#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Inducteurs du cytochrome P-450 CYP2D6",
"description": "Quels symptômes peuvent résulter d'une induction du CYP2D6 ?\nComment l'induction affecte-t-elle les médicaments ?\nY a-t-il des effets secondaires liés aux inducteurs ?\nQuels signes cliniques peuvent alerter sur une induction ?\nL'induction peut-elle causer des symptômes d'intoxication ?",
"url": "https://questionsmedicales.fr/mesh/D065699?mesh_terms=Tuberculosis#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Inducteurs du cytochrome P-450 CYP2D6",
"description": "Comment prévenir l'induction du CYP2D6 ?\nLes patients doivent-ils être informés des inducteurs ?\nQuelles précautions prendre lors de la prescription ?\nLes médecins doivent-ils surveiller les inducteurs ?\nY a-t-il des recommandations pour les prescripteurs ?",
"url": "https://questionsmedicales.fr/mesh/D065699?mesh_terms=Tuberculosis#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Inducteurs du cytochrome P-450 CYP2D6",
"description": "Comment gérer l'induction du CYP2D6 ?\nPeut-on utiliser des inhibiteurs du CYP2D6 ?\nQuels médicaments sont souvent ajustés ?\nY a-t-il des alternatives aux inducteurs ?\nComment surveiller l'efficacité du traitement ?",
"url": "https://questionsmedicales.fr/mesh/D065699?mesh_terms=Tuberculosis#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Inducteurs du cytochrome P-450 CYP2D6",
"description": "Quelles complications peuvent survenir avec l'induction ?\nL'induction peut-elle entraîner des hospitalisations ?\nQuels risques sont associés à l'induction ?\nComment gérer les complications liées à l'induction ?\nY a-t-il des complications à long terme ?",
"url": "https://questionsmedicales.fr/mesh/D065699?mesh_terms=Tuberculosis#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Inducteurs du cytochrome P-450 CYP2D6",
"description": "Quels sont les facteurs de risque d'induction ?\nL'âge influence-t-il l'induction du CYP2D6 ?\nLes habitudes de vie jouent-elles un rôle ?\nY a-t-il des prédispositions génétiques ?\nLes interactions médicamenteuses sont-elles un facteur ?",
"url": "https://questionsmedicales.fr/mesh/D065699?mesh_terms=Tuberculosis#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment identifier un inducteur du CYP2D6 ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'identification se fait par l'analyse des médicaments et leur effet sur le métabolisme."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'activité du CYP2D6 ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests génétiques et des dosages de médicaments peuvent être utilisés."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une induction du CYP2D6 ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une diminution de l'efficacité des médicaments métabolisés par CYP2D6 peut indiquer une induction."
}
},
{
"@type": "Question",
"name": "Peut-on mesurer l'activité du CYP2D6 ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'activité peut être mesurée par des tests de métabolisme de médicaments spécifiques."
}
},
{
"@type": "Question",
"name": "Quels médicaments sont des inducteurs connus ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des médicaments comme la rifampicine et la carbamazépine sont des inducteurs connus."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent résulter d'une induction du CYP2D6 ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une induction peut entraîner une réduction de l'efficacité des médicaments, causant des symptômes de maladie."
}
},
{
"@type": "Question",
"name": "Comment l'induction affecte-t-elle les médicaments ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut réduire la concentration plasmatique des médicaments, diminuant leur effet thérapeutique."
}
},
{
"@type": "Question",
"name": "Y a-t-il des effets secondaires liés aux inducteurs ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des effets secondaires peuvent survenir si les médicaments perdent leur efficacité."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques peuvent alerter sur une induction ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes de non-réponse au traitement peuvent alerter sur une induction du CYP2D6."
}
},
{
"@type": "Question",
"name": "L'induction peut-elle causer des symptômes d'intoxication ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Indirectement, si des médicaments sont sous-dosés, cela peut entraîner des symptômes d'intoxication."
}
},
{
"@type": "Question",
"name": "Comment prévenir l'induction du CYP2D6 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter les inducteurs connus et surveiller les interactions médicamenteuses."
}
},
{
"@type": "Question",
"name": "Les patients doivent-ils être informés des inducteurs ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'éducation des patients sur les inducteurs est cruciale pour éviter des complications."
}
},
{
"@type": "Question",
"name": "Quelles précautions prendre lors de la prescription ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Évaluer les antécédents médicamenteux et les interactions potentielles avant de prescrire."
}
},
{
"@type": "Question",
"name": "Les médecins doivent-ils surveiller les inducteurs ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une surveillance régulière des médicaments inducteurs est recommandée."
}
},
{
"@type": "Question",
"name": "Y a-t-il des recommandations pour les prescripteurs ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des lignes directrices existent pour éviter les interactions avec les inducteurs."
}
},
{
"@type": "Question",
"name": "Comment gérer l'induction du CYP2D6 ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il est essentiel d'ajuster les doses des médicaments affectés par l'induction."
}
},
{
"@type": "Question",
"name": "Peut-on utiliser des inhibiteurs du CYP2D6 ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des inhibiteurs peuvent être utilisés pour contrer l'effet des inducteurs."
}
},
{
"@type": "Question",
"name": "Quels médicaments sont souvent ajustés ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antidépresseurs et les antipsychotiques sont souvent ajustés en cas d'induction."
}
},
{
"@type": "Question",
"name": "Y a-t-il des alternatives aux inducteurs ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des médicaments non inducteurs peuvent être prescrits pour éviter l'interaction."
}
},
{
"@type": "Question",
"name": "Comment surveiller l'efficacité du traitement ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des suivis réguliers et des dosages de médicaments sont nécessaires pour évaluer l'efficacité."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec l'induction ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications incluent une inefficacité thérapeutique et des effets indésirables."
}
},
{
"@type": "Question",
"name": "L'induction peut-elle entraîner des hospitalisations ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des hospitalisations peuvent être nécessaires en cas de complications graves."
}
},
{
"@type": "Question",
"name": "Quels risques sont associés à l'induction ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les risques incluent des interactions médicamenteuses et des effets secondaires graves."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications liées à l'induction ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il est crucial d'ajuster les traitements et de surveiller les patients de près."
}
},
{
"@type": "Question",
"name": "Y a-t-il des complications à long terme ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications à long terme peuvent inclure des effets résiduels sur le métabolisme."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque d'induction ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'utilisation de certains médicaments et des variations génétiques."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il l'induction du CYP2D6 ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'âge peut affecter le métabolisme et la réponse aux inducteurs."
}
},
{
"@type": "Question",
"name": "Les habitudes de vie jouent-elles un rôle ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des habitudes comme l'alcool et le tabac peuvent influencer l'induction."
}
},
{
"@type": "Question",
"name": "Y a-t-il des prédispositions génétiques ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines variations génétiques peuvent augmenter le risque d'induction."
}
},
{
"@type": "Question",
"name": "Les interactions médicamenteuses sont-elles un facteur ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les interactions avec d'autres médicaments peuvent augmenter le risque d'induction."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 24/02/2025
Contenu vérifié selon les dernières recommandations médicales
4 publications dans cette catégorie
Affiliations :
Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation, Department of Pediatrics, Children's Mercy Kansas City, Kansas City, Missouri, USA.
School of Medicine, University of Missouri-Kansas City, Kansas City, Missouri, USA.
Publications dans "Inducteurs du cytochrome P-450 CYP2D6" :
2 publications dans cette catégorie
Affiliations :
Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation, Department of Pediatrics, Children's Mercy Kansas City, Kansas City, Missouri, USA.
School of Medicine, University of Missouri-Kansas City, Kansas City, Missouri, USA.
Publications dans "Inducteurs du cytochrome P-450 CYP2D6" :
2 publications dans cette catégorie
Affiliations :
School of Medicine, University of Missouri-Kansas City, Kansas City, Missouri, USA.
Biostatistics & Epidemiology Core, Division of Health Services and Outcomes Research, Department of Pediatrics, Children's Mercy Kansas City, Kansas City, Missouri, USA.
Division of Developmental and Behavioral Sciences, Department of Pediatrics, Children's Mercy Kansas City, Kansas City, Missouri, USA.
Publications dans "Inducteurs du cytochrome P-450 CYP2D6" :
2 publications dans cette catégorie
Affiliations :
Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation, Department of Pediatrics, Children's Mercy Kansas City, Kansas City, Missouri, USA.
School of Medicine, University of Missouri-Kansas City, Kansas City, Missouri, USA.
Publications dans "Inducteurs du cytochrome P-450 CYP2D6" :
2 publications dans cette catégorie
Affiliations :
Department of Biomedical Science, University of Nottingham, Malaysia Campus, Semenyih, Selangor, Malaysia.
Publications dans "Inducteurs du cytochrome P-450 CYP2D6" :
2 publications dans cette catégorie
Affiliations :
School of Pharmacy, International Medical University, Kuala Lumpur, Malaysia.
Publications dans "Inducteurs du cytochrome P-450 CYP2D6" :
2 publications dans cette catégorie
Affiliations :
Clinical Pharmacology Unit, Zealand University Hospital, Sygehusvej 10, 4000 Roskilde, Denmark.
Department of Clinical Medicine, University of Copenhagen, 2200 Copenhagen, Denmark.
Publications dans "Inducteurs du cytochrome P-450 CYP2D6" :
2 publications dans cette catégorie
Affiliations :
Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, Canada.
Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada.
Publications dans "Inducteurs du cytochrome P-450 CYP2D6" :
2 publications dans cette catégorie
Affiliations :
Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, Canada.
Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada.
Publications dans "Inducteurs du cytochrome P-450 CYP2D6" :
2 publications dans cette catégorie
Affiliations :
Laboratory of Metabolism, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Publications dans "Inducteurs du cytochrome P-450 CYP2D6" :
2 publications dans cette catégorie
Affiliations :
Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, Canada.
Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada.
Publications dans "Inducteurs du cytochrome P-450 CYP2D6" :
2 publications dans cette catégorie
Affiliations :
Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, Canada. r.tyndale@utoronto.ca.
Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada. r.tyndale@utoronto.ca.
Department of Psychiatry, University of Toronto, 1 King's College Circle, Toronto, Ontario, M5S 1A8, Canada. r.tyndale@utoronto.ca.
Publications dans "Inducteurs du cytochrome P-450 CYP2D6" :
2 publications dans cette catégorie
Affiliations :
PharmGenetix GmbH, Niederalm, Austria.
Publications dans "Inducteurs du cytochrome P-450 CYP2D6" :
2 publications dans cette catégorie
Affiliations :
Mental Health Neuroscience Research Department, Division of Psychiatry, University College London, London, UK.
Publications dans "Inducteurs du cytochrome P-450 CYP2D6" :
2 publications dans cette catégorie
Affiliations :
Mental Health Neuroscience Research Department, Division of Psychiatry, University College London, London, UK.
Publications dans "Inducteurs du cytochrome P-450 CYP2D6" :
2 publications dans cette catégorie
Affiliations :
Mental Health Neuroscience Research Department, Division of Psychiatry, University College London, London, UK.
Publications dans "Inducteurs du cytochrome P-450 CYP2D6" :
2 publications dans cette catégorie
Affiliations :
Mental Health Neuroscience Research Department, Division of Psychiatry, University College London, London, UK.
Publications dans "Inducteurs du cytochrome P-450 CYP2D6" :
2 publications dans cette catégorie
Affiliations :
Mental Health Neuroscience Research Department, Division of Psychiatry, University College London, London, UK. e.bramon@ucl.ac.uk.
Institute of Psychiatry, Psychology and Neuroscience, King's College London and South London and Maudsley NHS Foundation Trust, London, UK. e.bramon@ucl.ac.uk.
Institute of Cognitive Neuroscience, University College London, London, UK. e.bramon@ucl.ac.uk.
Publications dans "Inducteurs du cytochrome P-450 CYP2D6" :
2 publications dans cette catégorie
Affiliations :
Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.
Publications dans "Inducteurs du cytochrome P-450 CYP2D6" :
2 publications dans cette catégorie
Affiliations :
Center for Psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway.
Department of Pharmacy, University of Oslo, Oslo, Norway.
Publications dans "Inducteurs du cytochrome P-450 CYP2D6" :
Tuberculosis (TB) is a major cause of ill health and one of the leading causes of death worldwide. The first step in developing strategies to reduce TB mortality is to identify the direct causes of de...
Data on patients with TB systemically collected from the National Surveillance System of South Korea from January 2019 to December 2020 were included in this study. We analyzed the clinical characteri...
Of the total of 12,340 patients with TB, 61% were males with a mean age of 61.3 years. During the follow-up period, the overall mortality rate was 10.6%, with TB-related deaths accounting for 21.3% of...
Patients with high-risk TB must be identified through cause-specific mortality analysis, and the mortality rate must be reduced through intensive monitoring of patients with a high TB burden and comor...
Breast tuberculosis (TB) is a rare extra-pulmonary presentation of tuberculosis. In the western world, this accounts for less than 0.1% of breast conditions (all breast conditions, not limited to TB o...
We report a case of a 54-year- old human immunodeficiency virus (HIV)-positive lady who presented with six months history of multiple masses on the left breast which were initially suspected to be can...
Presentation of TB can be non-specific and atypical in patients with HIV infection, especially when it presents in extra-pulmonary forms....
Elimination of tuberculosis (TB) is defined as reducing TB disease incidence in the United States to less than 1 case per million persons per year. In 2022, TB incidence in the United States was 2.5 T...
The 5-year period for which the most recent data were available for each of five indicators: 1) overall TB incidence (2018-2022), 2) TB incidence among non-U.S.-born persons (2018-2022), 3) percentage...
The National TB Indicators Project (NTIP) is a web-based performance monitoring tool that uses national TB surveillance data reported through the National TB Surveillance System and the Aggregate Repo...
During the 5-year period for which the most recent data were available, most TB programs had improvements in reducing overall TB incidence (71.2%) and increasing the percentage of contacts receiving a...
This report is the first to describe a 5-year relative change for TB program performance. These results suggest that TB programs are making improvements in activities that help identify persons with T...
Use of NTIP data from individual TB programs enables a more detailed examination of trends in program performance and identification of areas for program improvement. Assessing indicator trends by TB ...
We discuss the most recent literature to support the identification of children at risk for tuberculosis and optimal testing and treatment strategies....
The identification and management of children with tuberculosis has increased in complexity due to the recent severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) pandemic, greater use of immu...
The SARS-CoV-2 pandemic will likely have a negative impact on global tuberculosis control. It is important that countries maintain a comprehensive approach to the identification and management of chil...
Due to COVID-19 pandemic, the latest progress of the End Tuberculosis (TB) Strategy was far from optimal and services for TB needs to be quickly restored. Pregnancy is a unique opportunity to screen a...
The Center for Personalized Precision Medicine of Tuberculosis (cPMTb) was constructed to develop personalized pharmacotherapeutic systems for tuberculosis (TB). This study aimed to introduce the cPMT...
Until August 2021, 964, 167, and 95 patients with TB, NTM infection, and LTBI, respectively, were included. Clinical, laboratory, and radiographic data were collected. NAT2 and SLCO1B1 phenotypes were...
Patients with TB were older, had lower body mass index (BMI), higher diabetes rate, and higher male proportion than patients with LTBI. Patients with NTM infection were older, had lower BMI, lower dia...
Understanding disease characteristics and identifying pharmacokinetic traits are fundamental steps in optimizing treatment. Further longitudinal data are required for personalized precision medicine....
This study registered ClinicalTrials.gov NO. NCT05280886....
Extrapulmonary tuberculosis (TB) presents unique diagnostic and therapeutic challenges. The site of involvement can vary widely, with common sites including the lymph nodes, pleura, skin, ear, nose an...
Tuberculosis (TB) is a significant public health problem among the Saharia community, an underprivileged tribal group in the west-central part of India. There are several challenges for India's TB con...
Despite concerted efforts, Mycobacterium tuberculosis (M.tb), the pathogen that causes tuberculosis (TB), continues to be a burden on global health, regaining its dubious distinction in 2022 as the wo...
In this review, we discuss the application of a novel replicating RNA (repRNA)-based vaccine formulated and delivered in nanostructured lipids....
Our preclinical data are the first to report that RNA platforms are a viable system for TB vaccines and should be pursued with high-priority M.tb antigens containing cluster of differentiation (CD4+) ...
This RNA vaccine shows promise for use against intracellular bacteria such as M.tb as demonstrated by the feasibility of construction, enhanced induction of cell-mediated and humoral immune responses,...
Early and rapid diagnosis of Mycobacterium tuberculosis in clinical specimen is important for the treatment of patients and control of disease transmission to the community. The disease is largely pre...